{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T18:24:25Z","timestamp":1778091865682,"version":"3.51.4"},"reference-count":133,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T00:00:00Z","timestamp":1619308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>New drugs were recently developed to treat hyperglycemia in patients with type 2 diabetes mellitus (T2D). However, metformin remains the first-line anti-diabetic agent because of its cost-effectiveness. It has pleiotropic action that produces cardiovascular benefits, and it can be useful in diabetic nephropathy, although metformin-associated lactic acidosis is a hindrance to its use in patients with kidney failure. New anti-diabetic agents, including glucagon-like peptide-1 receptor (GLP-1R) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose transporter-2 (SGLT-2) inhibitors, also produce cardiovascular or renal benefits in T2D patients. Their glucose-independent beneficial actions can lead to cardiorenal protection via hemodynamic stabilization and inflammatory modulation. Systemic hypertension is relieved by natriuresis and improved vascular dysfunction. Enhanced tubuloglomerular feedback can be restored by SGLT-2 inhibition, reducing glomerular hypertension. Patients with non-diabetic kidney disease might also benefit from those drugs because hypertension, proteinuria, oxidative stress, and inflammation are common factors in the progression of kidney disease, irrespective of the presence of diabetes. In various animal models of non-diabetic kidney disease, metformin, GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors were favorable to kidney morphology and function. They strikingly attenuated biomarkers of oxidative stress and inflammatory responses in diseased kidneys. However, whether those animal results translate to patients with non-diabetic kidney disease has yet to be evaluated. Considering the paucity of new agents to treat kidney disease and the minimal adverse effects of metformin, GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors, these anti-diabetic agents could be used in patients with non-diabetic kidney disease. This paper provides a rationale for clinical trials that apply metformin, GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors to non-diabetic kidney disease.<\/jats:p>","DOI":"10.3390\/life11050389","type":"journal-article","created":{"date-parts":[[2021,4,25]],"date-time":"2021-04-25T22:31:39Z","timestamp":1619389899000},"page":"389","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9886-8339","authenticated-orcid":false,"given":"Sungjin","family":"Chung","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8445-9892","authenticated-orcid":false,"given":"Gheun-Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000495557","article-title":"For the World Kidney Day Steering Committee Burden, Access, and Disparities in Kidney Disease","volume":"141","author":"Crews","year":"2019","journal-title":"Nephron"},{"key":"ref_2","unstructured":"(2021, April 21). 2020 Annual Data Report from the United States Renal Data System. Available online: https:\/\/adr.usrds.org\/2020\/end-stage-renal-disease."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"356","DOI":"10.23876\/j.krcp.20.040","article-title":"Patient characteristics according to rehabilitation and employment status in Korean hemodialysis patients","volume":"39","author":"Lee","year":"2020","journal-title":"Kidney Res. Clin. Pr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/eurheartj\/ehp604","article-title":"Heart failure events with rosiglitazone in type 2 diabetes: Data from the RECORD clinical trial","volume":"31","author":"Komajda","year":"2010","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND Investigators. Dulaglutide and car-diovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","article-title":"Dulaglutide and renal outcomes in type 2 diabetes: An exploratory analysis of the REWIND randomised, placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"CARMELINA Investi-gators. Effect of linagliptin vs. placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cphy.c130040","article-title":"Classical Renin-Angiotensin System in Kidney Physiology","volume":"4","author":"Sparks","year":"2014","journal-title":"Compr. Physiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: Results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1001\/jama.2019.3805","article-title":"Metformin","volume":"321","author":"Flory","year":"2019","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000481951","article-title":"Renoprotective effects of metformin","volume":"138","author":"Kajbaf","year":"2018","journal-title":"Nephron"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Corremans, R., Vervaet, B.A., D\u2019Haese, P.C., Neven, E., and Verhulst, A. (2018). Metformin: A Candidate Drug for Renal Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010042"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8742","DOI":"10.18632\/aging.103095","article-title":"Metformin: The updated protective property in kidney disease","volume":"12","author":"Pan","year":"2020","journal-title":"Aging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1007\/s003300050746","article-title":"Contrast media and metformin: Guidelines to diminish the risk of lactic acidosis in non-insulin-dependent diabetics after administration of contrast media","volume":"9","author":"Thomsen","year":"1999","journal-title":"Eur. Radiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1148\/radiol.09090690","article-title":"Systematic Review of Current Guidelines, and Their Evidence Base, on Risk of Lactic Acidosis after Administration of Contrast Medium for Patients Receiving Metformin 1","volume":"254","author":"Goergen","year":"2010","journal-title":"Radiology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1007\/s00330-017-5247-4","article-title":"Post-contrast acute kidney injury. Part 2: Risk stratification, role of hydration and other prophylactic measures, patients taking metformin and chronic dialysis patients: Recommendations for updated ESUR Contrast Medium Safety Committee guidelines","volume":"28","author":"Reimer","year":"2018","journal-title":"Eur. Radiol."},{"key":"ref_21","unstructured":"(2021, April 21). European Society of Urogenital Radiology Guidelines on Contrast Media. Available online: www.esur.org\/guidelines\/."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.23876\/j.krcp.20.012","article-title":"Metformin treatment for patients with diabetes and chronic kidney disease: A Korean Diabetes Association and Korean Society of Nephrology consensus statement","volume":"39","author":"Hur","year":"2020","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12872-020-01474-5","article-title":"Effect of continuous use of metformin on kidney function in diabetes patients with acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"20","author":"Yu","year":"2020","journal-title":"BMC Cardiovasc. Disord."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10557-015-6618-1","article-title":"Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial","volume":"29","author":"Posma","year":"2015","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23975","DOI":"10.1038\/srep23975","article-title":"Metformin Protects Against Cisplatin-Induced Tubular Cell Apoptosis and Acute Kidney Injury via AMPK\u03b1-regulated Autophagy Induction","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_26","first-page":"98","article-title":"Beneficial Effects of AMP-Activated Protein Kinase Agonists in Kidney Ischemia-Reperfusion: Autophagy and Cellular Stress Markers","volume":"128","author":"Sharma","year":"2014","journal-title":"Nephron"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4161\/auto.6398","article-title":"Autophagy revisited: A conversation with Christian de Duve","volume":"4","author":"Klionsky","year":"2008","journal-title":"Autophagy"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.4161\/auto.19821","article-title":"Emerging role of autophagy in kidney function, diseases and aging","volume":"8","author":"Huber","year":"2012","journal-title":"Autophagy"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lin, T.-A., Wu, V.C.-C., and Wang, C.-Y. (2019). Autophagy in Chronic Kidney Diseases. Cells, 8.","DOI":"10.3390\/cells8010061"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/ki.2010.11","article-title":"Metformin prevents experimental gentamicin-induced nephropathy by a mitochondria-dependent pathway","volume":"77","author":"Morales","year":"2010","journal-title":"Kidney Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/08860229509036371","article-title":"Renal Cortical Mitochondria Are the Source of Oxygen Free Radicals Enhanced by Gentamicin","volume":"17","author":"Yang","year":"1995","journal-title":"Ren. Fail."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"244","DOI":"10.23876\/j.krcp.20.082","article-title":"Mitochondrial dysfunction in kidney injury, inflammation, and disease: Potential therapeutic approaches","volume":"39","author":"Bhatia","year":"2020","journal-title":"Kidney Res. Clin. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"F727","DOI":"10.1152\/ajprenal.00293.2013","article-title":"Induction of AMPK activity corrects early pathophysiological alterations in the subtotal nephrectomy model of chronic kidney disease","volume":"305","author":"Satriano","year":"2013","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.kint.2018.01.027","article-title":"Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone dis-order","volume":"94","author":"Neven","year":"2018","journal-title":"Kidney Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.mce.2015.06.006","article-title":"Metformin prevents renal interstitial fibrosis in mice with unilateral ureteral obstruction","volume":"412","author":"Cavaglieri","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/1440-1681.12748","article-title":"Metformin attenuates renal fibrosis in both AMPKalpha2-dependent and independent manners","volume":"44","author":"Feng","year":"2017","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Shen, Y., Miao, N., Xu, J., Gan, X., Xu, D., Zhou, L., Xue, H., Zhang, W., and Lu, L. (2016). Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17020146"},{"key":"ref_38","first-page":"1","article-title":"Metformin attenuates renal interstitial fibrosis through upregulation of Deptor in unilateral ureteral obstruction in rats","volume":"20","author":"Wang","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e14141","DOI":"10.14814\/phy2.14141","article-title":"Metformin modulates immune cell infiltration into the kidney during unilateral ureteral obstruction in mice","volume":"7","author":"Christensen","year":"2019","journal-title":"Physiol. Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.4049\/jimmunol.1403088","article-title":"Metformin suppresses systemic au-toimmunity in Roquinsan\/san mice through inhibiting B cell differentiation into plasma cells via regulation of AMPK\/mTOR\/STAT3","volume":"198","author":"Lee","year":"2017","journal-title":"J. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"173731","DOI":"10.1016\/j.ejphar.2020.173731","article-title":"Metformin reduces proteinuria in spontaneously hypertensive rats by activating the HIF-2\u03b1-VEGF-A pathway","volume":"891","author":"Liu","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1002\/jcp.25838","article-title":"Metformin attenuates albumin-induced alterations in renal tubular cells in vitro","volume":"232","author":"Allouch","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.kint.2020.04.059","article-title":"Does metformin do more benefit or harm in chronic kidney disease patients?","volume":"98","author":"Jouret","year":"2020","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Alam","year":"2019","journal-title":"Lancet"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1053\/j.ajkd.2015.07.037","article-title":"Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016","volume":"67","author":"Chebib","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"ref_46","first-page":"256","article-title":"Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"C1297","DOI":"10.1152\/ajpcell.00227.2002","article-title":"Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells","volume":"284","author":"Hallows","year":"2003","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1073\/pnas.1011498108","article-title":"Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis","volume":"108","author":"Takiar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-018-1090-3","article-title":"Metformin in autosomal dominant polycystic kidney disease: Experimental hy-pothesis or clinical fact?","volume":"19","author":"Pisani","year":"2018","journal-title":"BMC Nephrol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1159\/000488807","article-title":"A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease","volume":"47","author":"Seliger","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/1753-0407.12161","article-title":"Glucagon-like peptide 1-potentiated insulin secretion and proliferation of pancreatic \u03b2-cells","volume":"6","author":"Ma","year":"2014","journal-title":"J. Diabetes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/ki.2014.236","article-title":"The potential for renoprotection with incretin-based drugs","volume":"86","author":"Tanaka","year":"2014","journal-title":"Kidney Int."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrcardio.2011.211","article-title":"The effect of glucagon-like peptide 1 on cardiovascular risk","volume":"9","author":"Sivertsen","year":"2012","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/RLI.0b013e3181d2eed8","article-title":"Reactive Oxygen Species and the Pathogenesis of Radiocontrast-Induced Nephropathy","volume":"45","author":"Heyman","year":"2010","journal-title":"Investig. Radiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/1440-1681.12944","article-title":"The glucagon-like peptide-1 receptor agonist Exendin-4, ameliorates contrast-induced nephropathy through suppression of oxidative stress, vascular dysfunction and apoptosis independent of glycaemia","volume":"45","author":"Hussien","year":"2018","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jss.2013.06.042","article-title":"Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat","volume":"185","author":"Yang","year":"2013","journal-title":"J. Surg. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1681\/ASN.2013020134","article-title":"Protection of glucagon-like peptide-1 in cispla-tin-induced renal injury elucidates gut-kidney connection","volume":"24","author":"Katagiri","year":"2013","journal-title":"J. Am. Soc. Nephrol"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ajpath.2019.10.008","article-title":"Glucagon-like peptide-1 receptor agonism improves nephrotoxic serum nephritis by inhibiting T-cell proliferation","volume":"190","author":"Filippidou","year":"2020","journal-title":"Am. J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1160\/th14-03-0258","article-title":"Glucagon-like peptide-1 receptor agonist activation ameliorates venous thrombosis-induced arteriovenous fistula failure in chronic kidney disease","volume":"112","author":"Chien","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sadaghianloo, N., Contenti, J., Dardik, A., and Mazure, N.M. (2019). Role of hypoxia and metabolism in the development of neointimal hy-perplasia in arteriovenous fistulas. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215387"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Geenen, I.L., Kolk, F.F., Molin, D.G., Wagenaar, A., Compeer, M.G., Tordoir, J.H., Schurink, G.W., De Mey, J.G., and Post, M.J. (2016). Nitric oxide re-sistance reduces arteriovenous fistula maturation in chronic kidney disease in rats. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0146212"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2020). KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 98, S1\u2013S115.","DOI":"10.1016\/j.kint.2020.06.019"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0065-1281(11)80085-1","article-title":"Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney","volume":"92","author":"Kettmann","year":"1992","journal-title":"Acta Histochem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"F681","DOI":"10.1152\/ajprenal.00075.2012","article-title":"DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury","volume":"303","author":"Glorie","year":"2012","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1479-5876-11-270","article-title":"Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and in-flammatory reaction","volume":"11","author":"Chen","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/ndt\/gfy397","article-title":"Dipeptidyl peptidase-4 inhibitor teneligliptin accel-erates recovery from cisplatin-induced acute kidney injury by attenuating inflammation and promoting tubular regeneration","volume":"34","author":"Iwakura","year":"2019","journal-title":"Nephrol Dial. Transpl."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/j.1523-1755.2005.00275.x","article-title":"Renal SDF-1 signals mobilization and homing of CXCR4-positive cells to the kidney after ischemic injury","volume":"67","author":"Isaac","year":"2005","journal-title":"Kidney Int."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1152\/ajplegacy.1961.201.3.511","article-title":"Renal sodium transport and oxygen consumption","volume":"201","author":"Kiil","year":"1961","journal-title":"Am. J. Physiol. Content"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"F414","DOI":"10.1152\/ajprenal.00174.2007","article-title":"Dipeptidyl peptidase IV inhibition downregulates Na+ -H+ ex-changer NHE3 in rat renal proximal tubule","volume":"294","author":"Girardi","year":"2008","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"F1647","DOI":"10.1152\/ajprenal.00082.2009","article-title":"Regulation of Na+\/H+ exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells","volume":"297","author":"Malnic","year":"2009","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.phrs.2017.12.001","article-title":"Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials","volume":"129","author":"Coppolino","year":"2018","journal-title":"Pharm. Res."},{"key":"ref_75","unstructured":"(2021, April 21). MARLINA-T2D: Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects with Renal Disease with LINAgliptin, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01792518."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/0886022X.2017.1279553","article-title":"Renoprotective effects of a di-peptidyl peptidase 4 inhibitor in a mouse model of progressive renal fibrosis","volume":"39","author":"Uchida","year":"2017","journal-title":"Ren Fail."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4093\/dmj.2018.0271","article-title":"Evogliptin, a Dipeptidyl Peptidase-4 Inhibitor, Attenuates Renal Fibrosis Caused by Unilateral Ureteral Obstruction in Mice","volume":"44","author":"Kim","year":"2020","journal-title":"Diabetes Metab. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1038\/s41598-020-60336-4","article-title":"Linagliptin and telmisartan induced effects on renal and urinary exosomal miRNA expression in rats with 5\/6 nephrectomy","volume":"10","author":"Wiech","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.kint.2016.01.016","article-title":"The dipeptidyl peptidase inhibitor linagliptin and the angiotensin II receptor blocker telmisartan show renal benefit by different pathways in rats with 5\/6 nephrectomy","volume":"89","author":"Tsuprykov","year":"2016","journal-title":"Kidney Int."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Joo, K.W., Kim, S., Ahn, S.-Y., Chin, H.J., Chae, D.-W., Lee, J., Han, J.S., and Na, K.Y. (2013). Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-98"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"588","DOI":"10.14336\/AD.2019.0620","article-title":"Renoprotective effect of a dipeptidyl pep-tidase-4 inhibitor on aging mice","volume":"11","author":"Ban","year":"2020","journal-title":"Aging Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"F878","DOI":"10.1152\/ajprenal.00590.2014","article-title":"Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury","volume":"308","author":"Higashijima","year":"2015","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bph.15320","article-title":"The dipeptidyl peptidase 4 inhibitor linagliptin ameliorates renal injury and accelerated resolution in a rat model of crescentic nephritis","volume":"178","author":"Mayer","year":"2021","journal-title":"Br. J. Pharm."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/labinvest.2016.34","article-title":"DA-1229, a dipeptidyl peptidase IV inhibitor, protects against renal injury by preventing podocyte damage in an animal model of pro-gressive renal injury","volume":"96","author":"Lee","year":"2016","journal-title":"Lab. Investing."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1159\/000490688","article-title":"Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy","volume":"43","author":"Jo","year":"2018","journal-title":"Kidney Blood Press. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/hr.2014.173","article-title":"Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats","volume":"38","author":"Sufiun","year":"2015","journal-title":"Hypertens. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"8912768","DOI":"10.1155\/2019\/8912768","article-title":"Dipeptidyl peptidase 4 inhibition ameliorates chronic kidney disease in a model of salt-dependent hy-pertension","volume":"2019","author":"Cappetta","year":"2019","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejphar.2016.04.005","article-title":"Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats","volume":"783","author":"Uchii","year":"2016","journal-title":"Eur. J. Pharm."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diabres.2017.07.033","article-title":"Renal glucose metabolism in normal physiological conditions and in diabetes","volume":"133","author":"Alsahli","year":"2017","journal-title":"Diabetes Res. Clin. Pr."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1464-5491.2009.02894.x","article-title":"Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: Therapeutic im-plications","volume":"27","author":"Gerich","year":"2010","journal-title":"Diabet. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.metabol.2014.06.018","article-title":"The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors","volume":"63","author":"Wilding","year":"2014","journal-title":"Metabolism"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI2415","article-title":"Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus","volume":"102","author":"Meyer","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_93","first-page":"E1049","article-title":"Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes","volume":"287","author":"Meyer","year":"2004","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose Transporters in Human Renal Proximal Tubular Cells Isolated from the Urine of Patients with Non-Insulin-Dependent Diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2014.02.010","article-title":"Sodium\/glucose cotransporter 2 inhibitors and pre-vention of diabetic nephropathy: Targeting the renal tubule in diabetes","volume":"64","author":"Gabbai","year":"2014","journal-title":"Am. J. Kidney Dis."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1038\/ki.1996.265","article-title":"The hyperfiltration theory: A paradigm shift in nephrology","volume":"49","author":"Brenner","year":"1996","journal-title":"Kidney Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.117.028814","article-title":"Cardiorenal Syndrome Revisited","volume":"138","author":"Zannad","year":"2018","journal-title":"Circulation"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Kanduri, S.R., Kovvuru, K., Hansrivijit, P., Thongprayoon, C., Vallabhajosyula, S., Pivovarova, A.I., Chewcharat, A., Garla, V., Medaura, J., and Cheungpasitporn, W. (2020). SGLT2 Inhibitors and kidney outcomes in patients with chronic kidney disease. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092723"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3389\/fphys.2017.00074","article-title":"Stress Signal Network between Hypoxia and ER Stress in Chronic Kidney Disease","volume":"8","author":"Maekawa","year":"2017","journal-title":"Front. Physiol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1089\/ars.2009.2705","article-title":"Endoplasmic Reticulum Stress and Renal Disease","volume":"11","author":"Dickhout","year":"2009","journal-title":"Antioxid. Redox Signal."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nrneph.2017.129","article-title":"Endoplasmic reticulum stress, the unfolded protein response and autophagy in kidney diseases","volume":"13","author":"Cybulsky","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12659\/MSMBR.907775","article-title":"Phlorizin Exerts Direct Protective Effects on Palmitic Acid (PA)-Induced Endothelial Dysfunction by Activating the PI3K\/AKT\/eNOS Signaling Pathway and Increasing the Levels of Nitric Oxide (NO)","volume":"24","author":"Li","year":"2018","journal-title":"Med. Sci. Monit. Basic Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.13961","article-title":"Interplay of adenosine monophosphate-activated protein kinase\/sirtuin-1 activation and sodium influx inhibition mediates the renal benefits of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes: A novel conceptual framework","volume":"22","author":"Packer","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"ref_106","first-page":"016270","article-title":"Molecular, Cellular, and Clinical Evidence That Sodium-Glucose Cotransporter 2 Inhibitors Act as Neurohormonal Antagonists When Used for the Treatment of Chronic Heart Failure","volume":"9","author":"Packer","year":"2020","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Jaikumkao, K., Promsan, S., Thongnak, L., Swe, M.T., Tapanya, M., Htun, K.T., Kothan, S., Intachai, N., and Lungkaphin, A. (2021). Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK\/mTOR signaling pathway in obese rats. J. Cell. Physiol., 8.","DOI":"10.1002\/jcp.30316"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/dom.12917","article-title":"Sodi-um-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials","volume":"19","author":"Tang","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","article-title":"A role for tubular Na+\/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin","volume":"319","author":"Onishi","year":"2020","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.kint.2018.05.026","article-title":"Sodium glucose cotransporter 2 inhibition and renal ischemia: Implications for future clini-cal trials","volume":"94","author":"Cherney","year":"2018","journal-title":"Kidney Int."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Chang, Y.K., Choi, H., Jeong, J.Y., Na, K.R., Lee, K.W., Lim, B.J., and Choi, D.E. (2016). Dapagliflozin, SGLT2 Inhibitor, attenuates renal ische-mia-reperfusion injury. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0160478"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.kint.2018.05.002","article-title":"A sodium-glucose co-transporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice","volume":"94","author":"Zhang","year":"2018","journal-title":"Kidney Int."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"F1041","DOI":"10.1152\/ajprenal.00512.2019","article-title":"Canagliflozin reduces cisplatin uptake and activates Akt to protect against cisplatin-induced nephrotoxicity","volume":"318","author":"Song","year":"2020","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S2213-8587(20)30162-5","article-title":"DIAMOND investigators. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): A randomised, double-blind, crossover trial","volume":"8","author":"Cherney","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_116","first-page":"10","article-title":"Pathophysiology of glomerular hemodynamic adaptations to nephron loss","volume":"9","author":"Pelayo","year":"1989","journal-title":"Semin. Nephrol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Thai, K., Kepecs, D.M., and Gilbert, R.E. (2016). Sodium-glucose linked cotransporter-2 inhibition does not attenuate disease pro-gression in the rat remnant kidney model of chronic kidney disease. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0144640"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jphs.2017.10.006","article-title":"Effect of a SGLT2 inhibitor on the systemic and intrarenal renin\u2013angiotensin system in subtotally nephrectomized rats","volume":"137","author":"Li","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e13228","DOI":"10.14814\/phy2.13228","article-title":"Sodium glucose transporter-2 inhibition has no renoprotective effects on non-diabetic chronic kidney disease","volume":"5","author":"Ma","year":"2017","journal-title":"Physiol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.33594\/000000003","article-title":"Effects of the SGLT-2 Inhibitor Canagliflozin on Adenine-Induced Chronic Kidney Disease in Rats","volume":"52","author":"Ali","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"100049","DOI":"10.1016\/j.metop.2020.100049","article-title":"Low dose of sodium-glucose transporter 2 inhibitor ipragliflozin at-tenuated renal dysfunction and interstitial fibrosis in adenine-induced chronic kidney disease in mice without diabetes","volume":"7","author":"Yamato","year":"2020","journal-title":"Metab. Open"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e98720","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhib-itor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: A combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/s41440-019-0326-3","article-title":"Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats","volume":"42","author":"Kim","year":"2019","journal-title":"Hypertens. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2337\/dc20-2604","article-title":"Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients with Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial","volume":"44","author":"Scholtes","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/406960","article-title":"Roles of Inflammation, Oxidative Stress, and Vascular Dysfunction in Hypertension","volume":"2014","author":"Dinh","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000505144","article-title":"Renal Anti-Fibrotic Effect of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension","volume":"51","author":"Castoldi","year":"2020","journal-title":"Am. J. Nephrol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/s41440-020-0410-8","article-title":"Effects of an SGLT2 inhibitor on the salt sen-sitivity of blood pressure and sympathetic nerve activity in a nondiabetic rat model of chronic kidney disease","volume":"43","author":"Wan","year":"2020","journal-title":"Hypertens Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1753944720939383","DOI":"10.1177\/1753944720939383","article-title":"Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation","volume":"14","author":"Sano","year":"2020","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","article-title":"The role of renal hypoxia in the pathogenesis of diabetic kidney disease: A promising target for newer renoprotective agents including SGLT2 inhibitors?","volume":"98","author":"Hesp","year":"2020","journal-title":"Kidney Int."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.semnephrol.2019.10.006","article-title":"Role of Renal Hypoxia in the Progression from Acute Kidney Injury to Chronic Kidney Disease","volume":"39","author":"Ullah","year":"2019","journal-title":"Semin. Nephrol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1159\/000491551","article-title":"Renal Hypoxia: An Important Prognostic Marker in Patients with Chronic Kidney Disease","volume":"48","author":"Zhou","year":"2018","journal-title":"Am. J. Nephrol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","article-title":"Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial","volume":"9","author":"Zanchi","year":"2020","journal-title":"J. Am. Hear. Assoc."}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/5\/389\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:52:43Z","timestamp":1760161963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/11\/5\/389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,25]]},"references-count":133,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["life11050389"],"URL":"https:\/\/doi.org\/10.3390\/life11050389","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,25]]}}}